Latest & greatest articles for pregnancy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pregnancy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pregnancy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pregnancy

41. Cervical pessary for preventing preterm birth in twin pregnancies with maternal short cervix after an episode of threatened preterm labor: randomised controlled trial

Cervical pessary for preventing preterm birth in twin pregnancies with maternal short cervix after an episode of threatened preterm labor: randomised controlled trial No intervention has proved effective to date in reducing the spontaneous preterm birth rate in twin pregnancies following an episode of threatened preterm labor and with a short cervix remaining. This study was designed to ascertain whether cervical pessaries are useful in preventing spontaneous preterm birth in women with twin (...) pregnancies and a short cervix remaining after a threatened preterm labor episode.This open, randomized, controlled trial was conducted in 132 pregnant women who had not delivered 48 hours after a threatened preterm labor episode and had a short cervix remaining (≤20 mm between 240 and 296 weeks and ≤10 mm between 300 and 336 weeks). Patients were randomly assigned to cervical pessary (n = 67) or routine management (n = 65). The primary outcome was the spontaneous preterm birth rate before 34 weeks

2019 EvidenceUpdates

42. Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy

Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy Do Doxylamine/p xylamine/pyrido yridoxine (X xine (Xon onv vea) for treating ea) for treating nausea and v nausea and vomiting of pregnancy omiting of pregnancy Evidence summary Published: 24 June 2019 www.nice.org.uk/guidance/es20 pathways K Ke ey messages y messages The content of this evidence review was up-to-date in April 2019. See summaries of product characteristics (SPCs), British national formulary (BNF (...) ) or the Medicines and Healthcare products Regulatory Agency (MHRA) or NICE websites for up-to-date information. Xonvea (Alliance Pharmaceuticals) is a delayed-release tablet containing doxylamine succinate 10 mg (an antihistamine) and pyridoxine hydrochloride 10 mg (vitamin B6). In July 2018, it was granted a marketing authorisation for treating nausea and vomiting of pregnancy in women (aged 18 years or older) who do not respond to conservative management. Doxylamine/pyridoxine is taken every day

2019 National Institute for Health and Clinical Excellence - Advice

43. Self-reported Physical Health of Women Who Did and Did Not Terminate Pregnancy After Seeking Abortion Services: A Cohort Study. (PubMed)

Self-reported Physical Health of Women Who Did and Did Not Terminate Pregnancy After Seeking Abortion Services: A Cohort Study. Research demonstrates worse short-term morbidity and mortality associated with childbirth than with abortion, but little research has examined long-term physical health in women with unwanted pregnancies after abortion versus childbirth.To examine the physical health of women who seek and receive or are denied abortion.Prospective cohort study.30 U.S. abortion

2019 Annals of Internal Medicine

44. Association of Blood Donor Sex and Prior Pregnancy With Mortality Among Red Blood Cell Transfusion Recipients. (PubMed)

Association of Blood Donor Sex and Prior Pregnancy With Mortality Among Red Blood Cell Transfusion Recipients. Evidence regarding associations of blood donor sex with mortality among red blood cell transfusion recipients is conflicting.To study associations of donor sex and prior pregnancy with mortality of transfusion recipients.Data from 3 retrospective cohorts of transfusion recipients (the Kaiser Permanente Northern California [KPNC] and Recipient Epidemiology and Donor Evaluation Study-III

2019 JAMA

45. Critical Care in Pregnancy

Critical Care in Pregnancy Sign In (ACOG) Sign in to your ACOG account Email is required. Please enter valid Email. was not found in our system. Would you like to associated with your account? Forgot your email address? JSOG Member? © 2019 - American College of Obstetricians and Gynecologists

2019 American College of Obstetricians and Gynecologists

46. Pregnancy and Heart Disease

Pregnancy and Heart Disease Sign In (ACOG) Sign in to your ACOG account Email is required. Please enter valid Email. was not found in our system. Would you like to associated with your account? Forgot your email address? JSOG Member? © 2019 - American College of Obstetricians and Gynecologists

2019 American College of Obstetricians and Gynecologists

47. Viral rash in pregnancy

Viral rash in pregnancy Guidance on the investigation, diagnosis and management of viral illness, or exposure to viral rash illness, in pregnancy Guidance on the investigation, diagnosis and management of viral rash illness, or exposure to viral rash illness, in pregnancy 2 About Public Health England Public Health England exists to protect and improve the nation’s health and wellbeing, and reduce health inequalities. We do this through world-leading science, knowledge and intelligence (...) : @PHE_uk Facebook: www.facebook.com/PublicHealthEngland Prepared by: Nalini Iyanger, Helen Campbell, Gayatri Amirthalingam and Kevin Brown. For queries relating to this document, please contact: Immunisation.lead@phe.gov.uk Telephone: 0208 200 4000. Acknowledgements: The authors gratefully acknowledge the expert review and advice received from: ? The NHS Infectious Diseases in Pregnancy Screening (IDPS) Screening Midwives and Specialist Nurses forum ? Royal College of Obstetricians and Gynaecologists

2019 Public Health England

48. Cerclage for women with twin pregnancies: a systematic review and meta-analysis

Cerclage for women with twin pregnancies: a systematic review and meta-analysis This study was conducted to estimate whether cerclage could extend the prolongation of pregnancy, reduce the risk of preterm birth, and improve perinatal outcomes in women with twin pregnancies.We included randomized controlled trials and cohort studies comparing the efficacy of cerclage with no cerclage for women with twin pregnancies.The following databases were searched for all published studies that compared (...) cerclage placement with expectant management in twin pregnancies from inception to July 2018: Medline, EMBASE, Scopus, ClinicalTrials.gov, Web of Science, and Cochrane Library. Each report was reviewed for inclusion or exclusion standard, and data extraction was performed by 2 authors independently.A total of 16 studies with 1211 women that met the inclusion criteria were included in the final analysis. Our outcomes indicated that cerclage placement for twin pregnancies with a cervical length of <15 mm

2019 EvidenceUpdates

49. Methylphenidate (Ritalin and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects

Methylphenidate (Ritalin and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects Prescrire IN ENGLISH - Spotlight ''Methylphenidate (Ritalin° and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects'', 1 June 2019 {1} {1} {1} | | > > > Methylphenidate (Ritalin° and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Methylphenidate (Ritalin° and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects FEATURED REVIEW Methylphenidate is an amphetamine-like psychostimulant used in attention deficit hyperactivity disorder (ADHD). Recent studies have revealed important data about the consequences of in utero exposure

2019 Prescrire

50. Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes. (PubMed)

Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes. There are a number of ways of monitoring blood glucose in women with diabetes during pregnancy, with self-monitoring of blood glucose (SMBG) recommended as a key component of the management plan. No existing systematic reviews consider the benefits/effectiveness of different techniques of blood glucose monitoring on maternal and infant outcomes among pregnant women with pre-existing diabetes (...) . The effectiveness of the various monitoring techniques is unclear. This review is an update of a review that was first published in 2014 and subsequently updated in 2017.To compare techniques of blood glucose monitoring and their impact on maternal and infant outcomes among pregnant women with pre-existing diabetes.For this update, we searched Cochrane Pregnancy and Childbirth's Trials Register, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) (1 November 2018), and reference

2019 Cochrane

51. Management of Preexisting Diabetes in Pregnancy: A Review. (PubMed)

Management of Preexisting Diabetes in Pregnancy: A Review. The presence of preexisting type 1 or type 2 diabetes in pregnancy increases the risk of adverse maternal and neonatal outcomes, such as preeclampsia, cesarean delivery, preterm delivery, macrosomia, and congenital defects. Approximately 0.9% of the 4 million births in the United States annually are complicated by preexisting diabetes.Women with diabetes have increased risk for adverse maternal and neonatal outcomes, and similar risks (...) are present with type 1 and type 2 diabetes. Both forms of diabetes require similar intensity of diabetes care. Preconception planning is very important to avoid unintended pregnancies and to minimize risk of congenital defects. Hemoglobin A1c goals are less than 6.5% at conception and less than 6.0% during pregnancy. It is also critical to screen for and manage comorbid illnesses, such as retinopathy and nephropathy. Medications known to be unsafe in pregnancy, such as angiotensin-converting enzyme

2019 JAMA

52. A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy. (PubMed)

A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy. Bleeding in early pregnancy is strongly associated with pregnancy loss. Progesterone is essential for the maintenance of pregnancy. Several small trials have suggested that progesterone therapy may improve pregnancy outcomes in women who have bleeding in early pregnancy.We conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate progesterone, as compared with placebo, in women (...) with vaginal bleeding in early pregnancy. Women were randomly assigned to receive vaginal suppositories containing either 400 mg of progesterone or matching placebo twice daily, from the time at which they presented with bleeding through 16 weeks of gestation. The primary outcome was the birth of a live-born baby after at least 34 weeks of gestation. The primary analysis was performed in all participants for whom data on the primary outcome were available. A sensitivity analysis of the primary outcome

Full Text available with Trip Pro

2019 NEJM Controlled trial quality: predicted high

53. Herbal Medicinal Product Use During Pregnancy and the Postnatal Period: A Systematic Review

Herbal Medicinal Product Use During Pregnancy and the Postnatal Period: A Systematic Review To report the incidence and nature of herbal medicinal products' adverse events and herb-drug interactions used by some pregnant and postnatal women.The Allied and Complementary Medicine Database, the Cumulative Index to Nursing and Allied Health Literature, EMBASE, the Cochrane Library, MEDLINE, Scopus, Web of Science, and ClinicalTrials.gov were searched from inception until August 2018.Any studies (...) reporting adverse events, herb-drug interactions or absence thereof associated with herbal medicinal products used during pregnancy or the postnatal period were included. Conference abstracts, pilot studies, and nonhuman studies were excluded. All included studies were critically appraised by two independent reviewers.Database searches retrieved 3,487 citations. After duplicate removal and review of titles, abstracts, and full-text, 115 articles were critically appraised. After excluding irrelevant

2019 EvidenceUpdates

54. Doxylamine succinate and pyridoxine hydrochloride (Xonvea) for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management

Doxylamine succinate and pyridoxine hydrochloride (Xonvea) for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management 1 Published 13 May 2019 1 SMC2140 doxylamine succinate 10mg and pyridoxine hydrochloride 10mg gastro-resistant tablets (Xonvea®) Alliance Pharmaceuticals Limited 5 April 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (...) (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission doxylamine succinate and pyridoxine hydrochloride (Xonvea®) is not recommended for use within NHSScotland. Indication under review: the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. Doxylamine in combination with pyridoxine significantly improved symptoms of nausea and vomiting compared with placebo in women with nausea and vomiting

2019 Scottish Medicines Consortium

55. Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy

Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy Maternal administration of magnesium sulfate for longer than 5–7 days in pregnancy has (...) been associated with skeletal adverse effects and hypocalcaemia and hypermagnesemia in neonates. If use of magnesium sulfate in pregnancy is prolonged or repeated, consider monitoring of neonates for abnormal calcium and magnesium levels and skeletal adverse effects. Published 17 May 2019 From: Therapeutic area: , , , Contents Advice for healthcare professionals: maternal administration of magnesium sulfate for longer than 5–7 days in pregnancy may be associated with adverse effects in the foetus

2019 MHRA Drug Safety Update

56. BHIVA guidelines on the management of HIV in pregnancy and postpartum

BHIVA guidelines on the management of HIV in pregnancy and postpartum British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018 BHIVA guidelines on the management of HIV in pregnancy and postpartum 2 Guideline writing group Dr Yvonne Gilleece (Chair) Honorary Clinical Senior Lecturer and Consultant Physician in HIV and Genitourinary Medicine, Brighton and Sussex University Hospitals NHS Trust Dr Shema Tariq (Vice-chair) Postdoctoral Clinical Research Fellow (...) of Leicester NHS Trust Dr Luciana Rubinstein Consultant in Genitourinary Medicine, London North West Healthcare University NHS Trust, London Ms Sonali Sonecha Lead Directorate Pharmacist HIV/GUM, Chelsea and Westminster Healthcare NHS Foundation Trust, London Dr Lisa Thorley UK Community Advisory Board representative Dr Pat Tookey Honorary Senior Lecturer and Co-Investigator National Study of HIV in Pregnancy and Childhood, UCL Great Ormond Street Institute of Child Health, London Ms Jennifer Tosswill

2019 British HIV Association

57. Glucose screening in pregnancy and future risk of cardiovascular disease in women: a retrospective, population-based cohort study

Glucose screening in pregnancy and future risk of cardiovascular disease in women: a retrospective, population-based cohort study In studies to date, gestational diabetes has consistently been associated with an increased future risk of cardiovascular disease, irrespective of the antepartum screening protocol or diagnostic criteria by which gestational diabetes is diagnosed. We reasoned that the resultant heterogeneity in the severity of dysglycaemia in women with gestational diabetes suggests (...) that the relationship between gestational glycaemia and subsequent cardiovascular disease probably extends into the non-diagnostic range. Thus, we hypothesised that glucose screening in pregnancy would identify future risk of cardiovascular disease in women who did not have gestational diabetes.We did a population-based cohort study using information from health-care administrative databases from the Ministry of Health and Long Term Care of Ontario (Canada). We identified all women in Ontario who had a 50 g oral

2019 EvidenceUpdates

58. Guided imagery for treating hypertension in pregnancy. (PubMed)

Guided imagery for treating hypertension in pregnancy. Hypertension (high blood pressure) in pregnancy carries a high risk of maternal morbidity and mortality. Although antihypertensive drugs are commonly used, they have adverse effects on mothers and fetuses. Guided imagery is a non-pharmacological technique that has the potential to lower blood pressure among pregnant women with hypertension. Guided imagery is a mind-body therapy that involves the visualisation of various mental images (...) to facilitate relaxation and reduction in blood pressure.To determine the effect of guided imagery as a non-pharmacological treatment of hypertension in pregnancy and its influence on perinatal outcomes.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register, and two trials registers (October 2018). We also searched relevant conference proceedings and journals, and scanned the reference lists of retrieved studies.We included randomised controlled trials (RCTs). We would have included RCTs

2019 Cochrane

59. Screening for Elevated Blood Lead Levels in Childhood and Pregnancy: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. (PubMed)

Screening for Elevated Blood Lead Levels in Childhood and Pregnancy: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Elevated blood lead level is associated with serious, often irreversible, health consequences.To synthesize evidence on the effects of screening, testing, and treatment for elevated blood lead level in pregnant women and children aged 5 years and younger in the primary care setting to inform the US Preventive Services Task Force.Cochrane

2019 JAMA

60. Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial. (PubMed)

Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial. Intermittent treatment with sulfadoxine-pyrimethamine, recommended for prevention of malaria in pregnant women throughout sub-Saharan Africa, is threatened by parasite resistance. We assessed the efficacy and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine (...) as an alternative to sulfadoxine-pyrimethamine.We did a double-blind, randomised, controlled, superiority trial at one rural site in Uganda with high malaria transmission and sulfadoxine-pyrimethamine resistance. HIV-uninfected pregnant women between 12 and 20 weeks gestation were randomly assigned (1:1) to monthly intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine or dihydroartemisinin-piperaquine. The primary endpoint was the risk of a composite adverse birth outcome defined

2019 Lancet Controlled trial quality: predicted high